ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
ProMIS Neurosciences (Nasdaq: PMN) will present preclinical data on its lead product candidate, PMN310, at the 4th International Conference on Cognitive & Behavioral Neurosciences. The data supports PMN310's potential as an Alzheimer's disease treatment, highlighting its enhanced selectivity for toxic amyloid-beta oligomers (AßO). Key findings show:
1. PMN310 demonstrates little to no interaction with monomers
2. It's minimally impacted by excess monomer competition in binding to toxic oligomers
3. PMN310 doesn't bind to Aß plaque or vascular deposits
These characteristics could potentially reduce the risk of amyloid-related imaging abnormalities (ARIA). ProMIS recently reported positive topline data from the first four cohorts in its Phase 1a trial of PMN310, meeting objectives for tolerability, safety, and pharmacokinetics. The company plans to advance PMN310 into a Phase 1b study in Q4 2024.
ProMIS Neurosciences (Nasdaq: PMN) presenterà i dati preclinici sul suo principale candidato prodotto, PMN310, alla 4ª Conferenza Internazionale sulle Neuroscienze Cognitive e Comportamentali. I dati supportano il potenziale di PMN310 come trattamento per la malattia di Alzheimer, evidenziando la sua maggiore selettività per gli oligomeri tossici dell'amiloide-beta (AßO). I risultati chiave mostrano:
1. PMN310 dimostra poca o nessuna interazione con i monomeri
2. È minimamente influenzato dalla competizione degli eccessi di monomeri nel legame con gli oligomeri tossici
3. PMN310 non si lega a placca Aß o depositi vascolari
Queste caratteristiche potrebbero potenzialmente ridurre il rischio di anomalie di imaging correlate all'amiloide (ARIA). ProMIS ha recentemente riportato dati positivi dai primi quattro gruppi nel suo studio di Fase 1a di PMN310, raggiungendo gli obiettivi di tollerabilità, sicurezza e farmacocinetica. L'azienda prevede di avanzare PMN310 in uno studio di Fase 1b nel quarto trimestre del 2024.
ProMIS Neurosciences (Nasdaq: PMN) presentará datos preclínicos sobre su principal candidato a producto, PMN310, en la 4ª Conferencia Internacional sobre Neurociencias Cognitivas y Comportamentales. Los datos respaldan el potencial de PMN310 como tratamiento para la enfermedad de Alzheimer, destacando su mayor selectividad por los oligómeros tóxicos de amiloide-beta (AßO). Los hallazgos clave muestran:
1. PMN310 demuestra poca o ninguna interacción con monómeros
2. Se ve mínimamente impactado por la competencia de monómeros en exceso para unirse a oligómeros tóxicos
3. PMN310 no se une a la placa Aß ni a depósitos vasculares
Estas características podrían potencialmente reducir el riesgo de anomalías en imágenes relacionadas con amiloides (ARIA). ProMIS informó recientemente datos positivos de las primeras cuatro cohortes en su ensayo de Fase 1a de PMN310, cumpliendo con los objetivos de tolerabilidad, seguridad y farmacocinética. La empresa planea avanzar PMN310 a un estudio de Fase 1b en el cuarto trimestre de 2024.
ProMIS Neurosciences (Nasdaq: PMN)는 제4회 국제 인지 및 행동 신경과학 회의에서 주요 제품 후보인 PMN310에 대한 전임상 데이터를 발표할 예정입니다. 이 데이터는 알츠하이머병 치료로서 PMN310의 잠재력을 뒷받침하며, 독성 아밀로이드-beta 올리고머(AßO)에 대한 향상된 선택성을 강조합니다. 주요 발견은 다음과 같습니다:
1. PMN310은 모노머와의 상호작용이 거의 없음
2. 독성 올리고머에 결합할 때 과잉 모노머 경쟁에 미미한 영향을 받음
3. PMN310은 Aß 플라크나 혈관 침착물에 결합하지 않음
이러한 특성은 아밀로이드 관련 이미징 이상(ARIA)의 위험을 줄일 수 있습니다. ProMIS는 최근 PMN310의 1상 시험에서 첫 번째 네 개의 집단에 대한 긍정적인 전체 데이터를 보고했으며, 내약성, 안전성 및 약동학에 대한 목표를 달성했습니다. 이 회사는 2024년 4분기에 PMN310을 1b상 연구로 진행할 계획입니다.
ProMIS Neurosciences (Nasdaq: PMN) présentera des données précliniques sur son principal candidat produit, PMN310, lors de la 4ᵉ Conférence Internationale sur les Neurosciences Cognitives et Comportementales. Les données soutiennent le potentiel de PMN310 comme traitement de la maladie d'Alzheimer, mettant en évidence sa sélectivité améliorée pour les oligomères toxiques de l'amiloïde-beta (AßO). Les principales conclusions montrent :
1. PMN310 montre peu ou pas d'interaction avec les monomères
2. Il est peu affecté par la compétition d'excès de monomères lors de la liaison aux oligomères toxiques
3. PMN310 ne se lie pas aux plaques Aß ni aux dépôts vasculaires
Ces caractéristiques pourraient potentiellement réduire le risque d'anomalies d'imagerie liées à l'amiloïde (ARIA). ProMIS a récemment rapporté des données positives des quatre premières cohortes de son essai de Phase 1a de PMN310, atteignant les objectifs de tolérabilité, de sécurité et de pharmacocinétique. L'entreprise prévoit de faire avancer PMN310 dans une étude de Phase 1b au quatrième trimestre 2024.
ProMIS Neurosciences (Nasdaq: PMN) wird auf der 4. Internationalen Konferenz über Kognitive und Verhaltensneuroscience präklinische Daten zu seinem Hauptproduktkandidaten, PMN310, präsentieren. Die Daten unterstützen das Potenzial von PMN310 als Behandlung für Alzheimer-Krankheit und heben die verbesserte Selektivität für toxische Amyloid-beta-Oligomere (AßO) hervor. Wichtige Ergebnisse zeigen:
1. PMN310 zeigt wenig bis keine Wechselwirkung mit Monomeren
2. Es wird minimal von einer Überkompensation der Monomeren beim Binden an toxische Oligomere beeinträchtigt
3. PMN310 bindet nicht an Aß Plaques oder vaskuläre Ablagerungen
Diese Eigenschaften könnten potenziell das Risiko von amiloidbezogenen Bildgebungsanomalien (ARIA) verringern. ProMIS berichtete kürzlich über positive Topline-Daten aus den ersten vier Kohorten seiner Phase-1a-Studie zu PMN310, wobei die Ziele für Verträglichkeit, Sicherheit und Pharmakokinetik erreicht wurden. Das Unternehmen plant, PMN310 im vierten Quartal 2024 in eine Phase-1b-Studie voranzubringen.
- PMN310 shows enhanced selectivity for toxic amyloid-beta oligomers in preclinical studies
- PMN310 demonstrates little to no interaction with monomers, potentially improving efficacy
- The antibody doesn't bind to Aß plaque or vascular deposits, potentially reducing ARIA risk
- Positive topline data from Phase 1a trial met objectives for tolerability, safety, and pharmacokinetics
- Company on track to advance PMN310 into Phase 1b study in Q4 2024
- None.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that preclinical data supporting the potential role of its lead product candidate, PMN310, as a treatment for AD will be highlighted in an oral presentation at the 4th International Conference on Cognitive & Behavioral Neurosciences (ICBN) taking place from September 12-13, 2024 in Lisbon, Portugal.
A large body of evidence indicates that the most pathogenic species of amyloid-beta (Aß) in AD consists of soluble toxic oligomers as opposed to insoluble fibrils and monomers. The ability of a therapeutic antibody to target toxic amyloid-beta oligomers (AßO) without being diverted by binding to competing non-toxic species has the potential to result in greater efficacy. As a next generation antibody, PMN310 is a therapeutic candidate designed to target toxic oligomers more selectively.
“The data being shared at ICBN further support PMN310 as a potential treatment for AD due to its enhanced selectivity for toxic oligomers” stated Johanne Kaplan, Ph.D., Chief Development Officer of ProMIS Neurosciences and platform presenter. “Importantly, the ability of PMN310 to avoid interaction with plaque and vascular deposits of amyloid-beta could potentially reduce the risk of amyloid-related imaging abnormalities, or ARIA, a dose-limiting toxicity associated with plaque-binding antibodies.”
In the studies, the binding of PMN310 and other Aß-directed antibodies to a toxic oligomer-enriched low molecular fraction of brain extract from AD patients was evaluated by surface plasmon resonance, with and without monomer competition. The results indicated that PMN310 showed little or no interaction with monomers and was among the least impacted by excess monomer competition in binding to toxic oligomers in AD brain extract. Additionally, PMN310 did not bind to Aß plaque or vascular deposits as determined by immunohistochemistry. These results highlight how PMN310 distinguishes itself from other Aß-directed antibodies and may potentially provide an improved product profile with enhanced efficacy.
Details of the oral presentation are as follows:
Title: Distinguishing between amyloid-beta directed antibodies: Ability of PMN310 to target toxic oligomers despite competing species
Date/Time of Virtual Presentation: Friday, September 13 at 2:00pm WEST (6:00am PT / 9:00am ET)
Authors: Johanne Kaplan, Ebrima Gibbs, Juliane Coutts, Beibei Zhao, Neil R. Cashman
The slide presentation is available on the Posters and Publications page of the Company’s website at www.promisneurosciences.com.
In July 2024, ProMIS Neurosciences reported positive topline data from the first four cohorts in its first-in-human Phase 1a clinical trial of PMN310, demonstrating that it met objectives for tolerability, safety and pharmacokinetics. The Company expects to report topline results from all five cohorts [in the coming months] and is on-track to advance PMN310 into a Phase 1b study in the fourth quarter of 2024.
About PMN310
PMN310 is a humanized monoclonal antibody (mAb) designed and developed based on its selectivity for soluble amyloid beta oligomers (AβOs), which ProMIS believes are the most toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaque. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, PMN310 aims to directly address the growing body of evidence suggesting that they represent a primary underlying cause of the neurodegenerative process in Alzheimer’s disease.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, “forward-looking information”) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “excited to”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the Company’s preclinical data, novel vaccine approach to target toxic oligomers and the potential implications thereof, the Company's expectations regarding its clinical development of its lead product, PMN310, for AD, and the Company’s plans to announce additional results and advance into a Phase 1b multiple ascending dose study in AD patients. Statements containing forward-looking information are not historical facts but instead represent management's current expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the risk that the results of nonclinical studies and early clinical trials are not necessarily predictive of future results with PMN310, the Company’s ability to fund its operations and continue as a going concern, its accumulated deficit and the expectation for continued losses and future financial results. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the “Risk Factors” section of the Company's most recently filed Annual Report on Form 10-K for the year ended December 31, 2023 and in its subsequent filings filed with the United States Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
For further information:
Visit us at www.promisneurosciences.com
Please submit media inquiries to info@promisneurosciences.com.
For Investor Relations, please contact:
Precision AQ (formerly Stern IR)
Anne Marie Fields, Managing Director
annemarie.fields@precisionaq.com
Tel. 212-362-1200
FAQ
What is PMN310 and how does it differ from other Alzheimer's treatments?
What were the key findings of the PMN310 preclinical studies presented at ICBN 2024?
What is the current development stage of PMN310 (Nasdaq: PMN) and what are the next steps?
How might PMN310's characteristics potentially reduce the risk of ARIA in Alzheimer's patients?
